Roivant Sciences Ltd. Common Shares earnings per share and revenue
On Nov 10, 2025, ROIV reported earnings of -0.17 USD per share (EPS) for Q2 26, beating the estimate of -0.34 USD, resulting in a 50.15% surprise. Revenue reached 1.57 million, compared to an expected 7.09 million, with a -77.83% difference. The market reacted with a +2.67% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Roivant Sciences Ltd. Common Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Roivant Sciences Ltd. Common Shares reported EPS of -$0.17, beating estimates by 50.15%, and revenue of $1.57M, -77.83% below expectations.
How did the market react to Roivant Sciences Ltd. Common Shares's Q2 2026 earnings?
The stock price moved up 2.67%, changed from $20.62 before the earnings release to $21.17 the day after.
When is Roivant Sciences Ltd. Common Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Roivant Sciences Ltd. Common Shares's next earnings report?
Based on --
analysts, Roivant Sciences Ltd. Common Shares is expected to report EPS of -- and revenue of -- for Q-- --.